From Wikipedia, the free encyclopedia
Jump to: navigation, search
Monoclonal antibody
Type Single-chain variable fragment
Source Human
Target fungal Hsp90
Clinical data
Trade names Mycograb
Routes of
ATC code
  • none
Pharmacokinetic data
Bioavailability Not applicable (IV only)
Protein binding High
Biological half-life 1–2 hours
  • none
Chemical and physical data
Molar mass Approximately 27.2 kg/mol
 NYesY (what is this?)  (verify)

Efungumab (trade name Mycograb) is a drug developed by NeuTec Pharma (a subsidiary of Novartis), intended to treat invasive Candida infection in combination with amphotericin B. The European Medicines Agency has twice refused to grant marketing authorization for Mycograb, citing product safety and quality issues.[1]

Chemically, efungumab is a single-chain variable fragment of a human monoclonal antibody.[2] As such, it potentially act similarly to an IgA - inhibiting by binding and blocking.

Its ability to potentiate the effects of the antifungal amphotericin B in culture were later found to be non-specific.[3]


  1. ^ European Medicines Agency (2007). "REFUSAL CHMP ASSESSMENT REPORT FOR MYCOGRAB. Procedure No. EMEA/H/C/658" (PDF).  (370 KiB). London: European Medicines Agency. Retrieved on 2007-11-20. Detailed assessment report with comprehensive overview of reasons for refusal of marketing authorization.
  2. ^ World Health Organization (2006). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 95" (PDF). WHO Drug Information. 20 (2): 48. 
  3. ^ Richie DL, Ghannoum MA, Isham N, Thompson KV, Ryder NS (2012). "Nonspecific effect of Mycograb on amphotericin B MIC". Antimicrob. Agents Chemother. 56 (7): 3963–4. doi:10.1128/AAC.00435-12. PMC 3393390Freely accessible. PMID 22508314.